RxDoctor Payments Data

Anthony Mikulec, MD

Otology & Neurotology · St. Louis, MONPI 1104843176

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,742 of the $3,028 with a category attached, or 90.5%. Otonomy, Inc. accounts for 90.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $2,217 and has fallen 95.8% since, to $94 in 2025.

$3,028in general payments, 2019–2025

Across 8 payments — averaging $378.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otonomy, Inc.$3K
  • Intersect ENT, Inc.$148
  • Regeneron Healthcare Solutions, Inc.$94
  • Johnson & Johnson$24
  • Optinose US, Inc.$20
$30,800in research payments, 2019–2025

Across 9 payments — averaging $3422.22 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Otonomy, Inc.$31K

What the payments were for

  • Consulting fees$2,74291%
  • Food & beverage$2879%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few otology & neurotology providers in Missourito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$71,617
Medicare patients
211
Services billed
854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth16$1,801
Diazepam79$427
Ofloxacin11$148

Paid to pharmacies, not to this prescriber.

Other otology & neurotology in St. Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →